AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers

Translational Psychiatry

Volumn 6, Issue 2, 2016, Pages

  Morgan, C J A ^a,b   Freeman, T P ^a   Powell, J ^c   Curran, H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; CATECHOL METHYLTRANSFERASE; PROTEIN KINASE B; PSYCHEDELIC AGENT; AKT1 PROTEIN, HUMAN; CANNABINOID;

ADOLESCENT; ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; DISEASE ASSOCIATION; FEMALE; GENE TARGETING; GENETIC VARIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; RISK FACTOR; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; WORKING MEMORY; ACUTE DISEASE; GENETIC PREDISPOSITION; GENETICS; MENTAL DISEASE; PSYCHOLOGY; RISK; SEX DIFFERENCE; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; CANNABINOIDS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MARIJUANA SMOKING; MENTAL DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; RISK; SEX FACTORS; YOUNG ADULT;

EID: 84964091075     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.219     Document Type: Article

References (39)

1. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–328.
2. Genetic Risk and Outcome in Psychosis (GROUP) Investigators. Evidence that familial liability for psychosis is expressed as differential sensitivity to csannabis: an analysis of patient-sibling and sibling-control pairs. Arch Gen Psychiatry 2011; 68: 138–147.
3. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117–1127.
4. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan MC et al. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry 2007; 191: 402–407.
5. Sanchez MG, Ruiz-Llorente L, Sanchez AM, Diaz-Laviada I. Activation of phos-phoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal 2003; 15: 851–859.
6. Ozaita A, Puighermanal E, Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007; 102: 1105–1114.
7. Bozzi Y, Dunleavy M, Henshall DC. Cell signaling underlying epileptic behavior. Front Behav Neurosci 2011; 5: 45.
8. van Winkel R, Henquet C, Rosa A, Papiol S, Fananas L, De Hert M et al. Evidence that the COMT(Val158Met) polymorphism moderates sensitivity to stress in psy-chosis: an experience-sampling study. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 10–17.
9. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012; 72: 811–816.
10. van Winkel R, van Beveren NJ, Simons C. Genetic R, Outcome of Psychosis I. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. Neuropsychopharmacology 2011; 36: 2529–2537.
11. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917–6922.
12. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R et al. Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J Clin Invest 2008; 118: 2200–2208.
13. Barkus E, Lewis S. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med 2008; 38: 1267–1276.
14. Morgan CJ, Schafer G, Freeman TP, Curran HV. Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry 2010; 197: 285–290.
15. Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010; 35: 1879–1885.
16. Mason OJ, Morgan CJ, Stefanovic A, Curran HV. The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and can-nabis. Schizophr Res 2008; 103: 138–142.
17. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull 1991; 17: 555–564.
18. van Winkel R. Genetic R, Outcome of Psychosis I. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up. Arch Gen Psychiatry 2011; 68: 148–157.
19. Arguello PA, Gogos JA. A signaling pathway AKTing up in schizophrenia. J Clin Invest 2008; 118: 2018–2021.
20. Howes J, Osgood P. The effect of delta9-tetrahydrocannabinol on the uptake and release of 14C-dopamine from crude striatal synaptosoma; preparations. Neuro-pharmacology 1974; 13: 1109–1114.
21. Graham JD, Lewis MJ, Williams J. Proceedings: the effect of delta-1-tetrahydrocannabinol on the noradrenaline and dopamine content of the brain and heart of the rat. Br J Pharmacol 1974; 52: 446P.
22. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009; 34: 759–766.
23. Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 2001; 107: 173–177.
24. Stokes PR, Egerton A, Watson B, Reid A, Lappin J, Howes OD et al. History of cannabis use is not associated with alterations in striatal dopamine D2/D3 receptor availability. J Psychopharmacol 2012; 26: 144–149.
25. Kapur S. How antipsychotics become anti-"psychotic"--from dopamine to salience to psychosis. Trends Pharmacol Sci 2004; 25: 402–406.
26. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neu-ropsychopharmacology 2006; 31: 2748–2757.
27. Zammit S, Owen MJ, Evans J, Heron J, Lewis G. Cannabis, COMT and psychotic experiences. Br J Psychiatry 2011; 199: 380–385.
28. Xu H, Kellendonk CB, Simpson EH, Keilp JG, Bruder GE, Polan HJ et al. DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. Schizophr Res 2007; 90: 104–107.
29. Bruder GE, Keilp JG, Xu H, Shikhman M, Schori E, Gorman JM et al. Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry 2005; 58: 901–907.
30. Barnett JH, Scoriels L, Munafo MR. Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism. Biol Psychiatry 2008; 64: 137–144.
31. Ziermans TB. Working memory capacity and psychotic-like experiences in a general population sample of adolescents and young adults. Front Psychiatry 2013; 4: 161.
32. Wood SJ, Pantelis C, Proffitt T, Phillips LJ, Stuart GW, Buchanan JA et al. Spatial working memory ability is a marker of risk-for-psychosis. Psychol Med 2003; 33: 1239–1247.
33. Carter C, Robertson L, Nordahl T, Chaderjian M, Kraft L, O'Shora-Celaya L. Spatial working memory deficits and their relationship to negative symptoms in unme-dicated schizophrenia patients. Biol Psychiatry 1996; 40: 930–932.
34. Menon V, Anagnoson RT, Mathalon DH, Glover GH, Pfefferbaum A. Functional neuroanatomy of auditory working memory in schizophrenia: relation to positive and negative symptoms. Neuroimage 2001; 13: 433–446.
35. Crane NA, Schuster RM, Gonzalez R. Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. J Int Neuropsychol Soc 2013; 19: 1009–1015.
36. Burston JJ, Wiley JL, Craig AA, Selley DE, Sim-Selley LJ. Regional enhancement of cannabinoid CB1 receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure. Br J Pharmacol 2010; 161: 103–112.
37. Rubino T, Vigano D, Realini N, Guidali C, Braida D, Capurro V et al. Chronic delta 9-tetrahydrocannabinol during adolescence provokes sex-dependent changes in the emotional profile in adult rats: behavioral and biochemical correlates. Neuropsychopharmacology 2008; 33: 2760–2771.
38. Van Laere K, Goffin K, Casteels C, Dupont P, Mortelmans L, de Hoon J et al. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 2008; 39: 1533–1541.
39. Narimatsu S, Watanabe K, Yamamoto I, Yoshimura H. Sex difference in the oxi-dative metabolism of delta 9-tetrahydrocannabinol in the rat. Biochem Pharmacol 1991; 41: 1187–1194.